16 Apr 2009
Following the discovery of an endogenous cannabinoid system and the identification of specific cannabinoid receptors in the central nervous system, much work has been done to investigate the main effects of these compounds. There is increasing evidence that the cannabinoid system may regulate neurodegenerative processes such as excessive glutamate production, oxidative stress and neuroinflammation.
Neurodegeneration is a feature common to the various types of dementia and this has led to interest in whether cannabinoids may be clinically useful in the treatment of people with dementia. Recent studies have also shown that cannabinoids may have more specific effects in interrupting the pathological process in Alzheimer's disease.
Extract from Implications for Practice
At present this review finds no evidence that cannabinoids are effective in the improvement of disturbed behaviour in dementia or in the treatment of other symptoms of dementia.
(CD007204) by Krishnan, Cairns and Howard
The Cochrane Library contains high quality health care information, including Systematic Reviews from The Cochrane Collaboration. These Reviews bring together research on the effects of health care and are considered the gold standard for determining the relative effectiveness of different interventions. The Cochrane Collaboration is a UK registered international charity and the world's leading producer of systematic Reviews. It has been demonstrated that Cochrane Systematic Reviews are of comparable or better quality and are updated more often than the Reviews published in print journals.
The Cochrane Library can be accessed at http://www.thecochranelibrary.com. Guest users may access abstracts for all Reviews in the database, and members of the media may request full access to the contents of the Library.
Source
The Cochrane Library
Article URL: http://www.medicalnewstoday.com/articles/146196.php
Main News Category: Alzheimer's / Dementia
Also Appears In: Seniors / Aging,
No comments:
Post a Comment